Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes.
alanine aminotransferase
aspartate aminotransferase
liver fat
non‐alcoholic fatty liver disease
sodium glucose cotransporter 2 inhibitors
type 2 diabetes
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
28
08
2020
revised:
17
11
2020
accepted:
25
11
2020
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
Sodium glucose cotransporter 2 inhibitors (SGLT-2i), by way of their unique mode of action, present an attractive strategy for the treatment of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), which often coexist and may lead to severe complications. However, the evidence for treatment with SGLT-2i is limited to small heterogeneous studies. Therefore, this meta-analysis was conducted to deduce the effects of SGLT-2i in NAFLD with type 2 diabetes (T2D). A web-based search identified nine randomized controlled trials from the Cochrane Library, Embase, and PubMed for this meta-analysis. The Comprehensive Meta-Analysis Software version 3 was used to calculate the effect size. The outcomes of interest were analyzed from a pooled population of 11 369 patients-7281 on SGLT-2i and 4088 in the control arm. SGLT-2i therapy produced a statistically significant improvement in alanine aminotransferase [standardised mean difference (SDM), -0.21, 95% confidence interval (CI), -0.32 to -0.10, This meta-analysis provides a convincing signal that SGLT-2i have a salutary effect on NAFLD in type 2 diabetes (T2D), probably driven by an improvement of glycemia and body weight, which in turn attenuates hepatic inflammation and hepatic fat accumulation.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Sodium glucose cotransporter 2 inhibitors (SGLT-2i), by way of their unique mode of action, present an attractive strategy for the treatment of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), which often coexist and may lead to severe complications. However, the evidence for treatment with SGLT-2i is limited to small heterogeneous studies. Therefore, this meta-analysis was conducted to deduce the effects of SGLT-2i in NAFLD with type 2 diabetes (T2D).
METHODS
METHODS
A web-based search identified nine randomized controlled trials from the Cochrane Library, Embase, and PubMed for this meta-analysis. The Comprehensive Meta-Analysis Software version 3 was used to calculate the effect size.
RESULT
RESULTS
The outcomes of interest were analyzed from a pooled population of 11 369 patients-7281 on SGLT-2i and 4088 in the control arm. SGLT-2i therapy produced a statistically significant improvement in alanine aminotransferase [standardised mean difference (SDM), -0.21, 95% confidence interval (CI), -0.32 to -0.10,
CONCLUSION
CONCLUSIONS
This meta-analysis provides a convincing signal that SGLT-2i have a salutary effect on NAFLD in type 2 diabetes (T2D), probably driven by an improvement of glycemia and body weight, which in turn attenuates hepatic inflammation and hepatic fat accumulation.
Identifiants
pubmed: 33553659
doi: 10.1002/jgh3.12473
pii: JGH312473
pmc: PMC7857274
doi:
Types de publication
Journal Article
Langues
eng
Pagination
219-227Informations de copyright
© 2020 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
J Hepatol. 2010 Aug;53(2):372-84
pubmed: 20494470
Clin Gastroenterol Hepatol. 2009 Nov;7(11):1224-9, 1229.e1-2
pubmed: 19559819
J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31
pubmed: 22238392
Clin Ther. 2015 Jun 01;37(6):1150-66
pubmed: 25891804
Int J Cancer. 2012 Apr 1;130(7):1639-48
pubmed: 21544812
Hepatol Res. 2019 May;49(5):531-539
pubmed: 30577089
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diabetes Obes Metab. 2020 Jan;22(1):128-134
pubmed: 31486260
Diabetes Care. 2007 May;30(5):1212-8
pubmed: 17277038
J Hepatol. 2009 Aug;51(2):371-9
pubmed: 19501928
Diabetologia. 2008 Mar;51(3):444-50
pubmed: 18058083
J Diabetes Investig. 2020 Sep;11(5):1238-1247
pubmed: 32083798
Diabetes Care. 2011 May;34(5):1139-44
pubmed: 21478462
Hepatology. 1999 Mar;29(3):664-9
pubmed: 10051466
Eur J Pharmacol. 2018 Jun 5;828:135-145
pubmed: 29608898
Am J Med. 1999 Nov;107(5):450-5
pubmed: 10569299
Diabetologia. 2018 Sep;61(9):1923-1934
pubmed: 29971527
Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700
pubmed: 24948511
Diabetes Care. 2018 Aug;41(8):1801-1808
pubmed: 29895557
World J Gastroenterol. 2015 Jun 14;21(22):6820-34
pubmed: 26078558
Diabetes Obes Metab. 2019 Feb;21(2):285-292
pubmed: 30178600
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937
Diabetes Obes Metab. 2018 Feb;20(2):370-377
pubmed: 28786557
Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55
pubmed: 23707905
Eur J Pharmacol. 2015 May 5;754:19-24
pubmed: 25701721
Diabetes Care. 2020 Feb;43(2):298-305
pubmed: 31540903
Diabetes Care. 2007 Aug;30(8):2119-21
pubmed: 17519430
Hepatology. 2003 Apr;37(4):917-23
pubmed: 12668987
Ann Intern Med. 2013 Aug 20;159(4):262-74
pubmed: 24026259
Frontline Gastroenterol. 2019 Oct;10(4):337-346
pubmed: 31682643
Diabetol Int. 2017 Jan 3;8(2):218-227
pubmed: 30603325
J Clin Med. 2019 Nov 01;8(11):
pubmed: 31683785
Diabetologia. 2018 Oct;61(10):2155-2163
pubmed: 30066148
J Clin Endocrinol Metab. 2015 Jun;100(6):2231-8
pubmed: 25885947
Metabolism. 2016 Aug;65(8):1096-108
pubmed: 26856933
Diabetes Obes Metab. 2018 Feb;20(2):438-442
pubmed: 28719078